Anemia
Conference Coverage
Sickle cell disease: What to watch at ASH
Dr. Alexis Thompson, ASH president, highlighted four top studies that will be presented at the meeting.
News
FDA approves first treatment for primary HLH
The U.S.
News
Adjunctive Promacta approved for first-line SAA
Among the patients treated at the recommended dosing schedule, the 6-month overall response rate was 79%, and the complete response rate was 44...
News
Eltrombopag approved as first-line SAA therapy
The U.S.
News
FDA approves generic decitabine for MDS
The U.S. Food and Drug Administration has approved Lupin’s decitabine product, a generic version of Otsuka Pharmaceutical Co.
News
Score can predict thrombosis in ITP
New research suggests a scoring system can predict the risk of thrombosis in patients with immune thrombocytopenia (ITP) who are taking...
News
Preoperative anemia management saves blood, money
BOSTON—Results of a pilot program suggest preoperative management of anemia can reduce transfusion rates and cut costs, but the effect on patient...
Conference Coverage
Preop anemia management saves blood, costs
BOSTON – Managing anemia prior to cardiac surgery saved a hospital more than $100,000 in transfusion costs in a pilot program.
News
Financial burden of blood cancers in the U.S.
An analysis of more than 2,000 U.S.
Conference Coverage
Researchers seek more sickle cell drug research
BETHESDA, MD – While there are experimental treatments such as ...
Conference Coverage
Antigen profiling may help prevent transfusion complications
BETHESDA, MD. – Extended red cell antigen profiling before initial transfusion can help avoid complications in highly transfused populations.